Ömer Faruk Bahçecioğlu

Ömer Faruk Bahçecioğlu

Auto-generated profile, based on publicly available information

Ömer Faruk Bahçecioğlu

Inonu University, Faculty of Pharmacy, Department of Clinical Pharmacy, Malatya, Turkey

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 September 2021 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
Zeynep ÖZDEMİRZeynep ÖZDEMİR
Zeynep ÖZDEMİR
MAMehmet Abdullah Alagöz
Mehmet Abdullah Alagöz
ÖBÖmer Faruk Bahçecioğlu
Ömer Faruk Bahçecioğlu
SGSelim Gök
Selim Gök
Background: The MAO enzyme is presented in the brain and peripheral tissues and is a significant enzyme that is responsible for the deamination of biogenic amines and thus the regulation of neurotransmitter levels. The reaction of these neurotransmitters with the MAO enzyme produces aldehyde and free amine. MAO enzyme consists of two isoforms, MAO-A and MAO-B, which are characterized by amino acid sequence, three-dimensional structure, substrate preference, and inhibitor selectivity. Dopamine, tyramine, and tryptamine are substrates of both MAO isoforms and MAO inhibitors such as clorgiline and selegiline, which are used as medications in neurodegenerative and neurological diseases. In particular, MAO-A inhibitors are used in the treatment of depression, while MAO-B inhibitors are used in the treatment of Parkinson's disease. It is also investigated whether MAO-B inhibitors are effective in the treatment of Alzheimer's disease. Nowadays, life expectancy has increased, as a result, neurodegenerative diseases such as Parkinson's and Alzheimer's disease have started to occur more frequently. The elderly population is increasing day by day. As a result of these common diseases in elderly people, these people are unable to do their jobs and need care. Therefore, these diseases have become a significant health problem in society. Methods: In this study, review, inclusion, and exclusion criteria were used. Peer-reviewed research articles were searched. The quality of the examined articles was evaluated with standard tools. The information obtained was analyzed conceptually by using qualitative content analysis methodology. Results: One hundred and five papers were included in the review. The current MAO-B inhibitors and their usage areas are discussed together with the structures of the drugs; also, their possible effects in Alzheimer’s and Parkinson’s treatment are evaluated. In addition, different articles have been compiled in which structures such as arylalkylamines, chalcones, benzoquinone, benzoxazinone, and chromen are substituted with various functional groups and aromatic rings, along with thestructures of 44 different compounds that have recently been developed and their inhibitory effects on MAO-B enzyme. As a result, the structure required for MAO-B inhibition and SAR studies is discussed. Conclusion: Many studies demonstrate that MAO-B activity increases with age in brain tissue, cerebrospinal fluid (CSF), and platelets in Alzheimer's patients. This suggests that MAO-B inhibitor drugs, which may be effective in the treatment of Parkinson's disease, may also be effective in the treatment of Alzheimer's disease. This article was written to explain the multifaceted MAO-B inhibitor molecules.

9 October 2021 in International Journal Of Clinical Practice
Verified
Journal Article
Open access
PDF file
SGSelim Gök
Selim Gök
ÖBÖmer Faruk Bahçecioğlu
Ömer Faruk Bahçecioğlu
MDMefküre Durmuş
Mefküre Durmuş
ZGZeynep Ülkü Gün
Zeynep Ülkü Gün
YEYasemin Ersoy
Yasemin Ersoy
ÖUÖzkan Ulutaş
Özkan Ulutaş
Objective The safety profile of favipiravir in patients with severe renal impairment has not been investigated and available data are insufficient. The study aimed to compare the incidence of favipiravir-associated adverse events amongst patients with varying renal function statuses. Methods Records of 921 patients who were hospitalised for COVID-19 and had received at least 5 days of favipiravir treatment were retrospectively evaluated and 228 patients were included in the study. Patients' age, sex, comorbidities, estimated glomerular filtration rate (eGFR) and haematological and biochemical values were recorded. The incidence of adverse events was compared with the age, sex, comorbidities and eGFR of the patients. Results The mean age of the patients was 59.3 +/- 15.6 years, and 38.2% of the patients were women. One hundred and thirty-one (57.5%) patients had experienced adverse events. These adverse effects consisted of ALT elevation (35.5%), AST elevation (21.5%), anaemia (16.2%), hyperuricaemia (10.5%), hepatocellular injury (9.2%), neutropenia (3.5%) and thrombocytopenia (2.6%). The incidence of adverse events was not significantly different when patients had eGFR >60 mL/min/1.73 m(2) or eGFR 30-60 mL/min/1.73 m(2) (P > .05), but significantly increased when the eGFR dropped to <30 (P < .05). The differences seen with hyperuricaemia and anaemia were significant (P < .05). Conclusion Even though favipiravir appeared to be well tolerated in the individuals with renal failure in this study, its use in this population remains a challenge that requires more research and analysis.

1 August 2021 in Transfusion and Apheresis Science
Verified
Journal Article
Closed access
ASAhmet Sarıcı
Ahmet Sarıcı
MEMehmet Ali Erkurt
Mehmet Ali Erkurt
ÖBÖmer Faruk Bahçecioğlu
Ömer Faruk Bahçecioğlu
SGSelim Gök
Selim Gök
IKİrFan Kuku
İrFan Kuku
MÖMustafa Özgül
Mustafa Özgül

1 January 2020 in Medicine Science | International Medical Journal
Verified
Journal Article
Open access
ZGZeynep Gun
Zeynep Gun
OBOmer Bahcecioglu
Omer Bahcecioglu
SGSelim Gok
Selim Gok


7 June 2022 in Transfusion and Apheresis Science
Verified
Journal Article
Closed access
ASAhmet Sarıcı
Ahmet Sarıcı
MEMehmet Ali Erkurt
Mehmet Ali Erkurt
IKİrFan Kuku
İrFan Kuku
EKEmin KAYA
Emin KAYA
IBİlHami Berber
İlHami Berber
AUAyse Uysal
Ayse Uysal